ANIK Q2 2023 Earnings — Anika Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ANIKAnika Therapeutics, Inc.

$213M

Q2 2023 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$44M+11.7% YoY

Gross Profit

$29M65.4% margin

Operating Income

-$4M-8.2% margin

Net Income

-$3M-6.2% margin

EPS (Diluted)

$-0.19

QoQ Revenue Growth

+16.8%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$10M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$329M

Total Liabilities

$55M

Stockholders' Equity

$274M

Cash & Equivalents

$65M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$44M	$40M	+11.7%
Gross Profit	$29M	$25M	+16.5%
Operating Income	-$4M	-$3M	-7.4%
Net Income	-$3M	-$3M	+3.6%

Revenue Segments

OA Pain Management

$29M66%

Joint Preservation and Restoration

$13M29%

Non-Orthopedic

$2M5%

Geographic Segments

UNITED STATES

$33M85%

Europe

$6M15%